Eli Lilly and Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and an EU Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for nasal glucagon. If the drug receives approval, it will be the first dry powder nasal spray on market to treat severe hypoglycemia.
Since it is just the powder, I would guess it is shelf-stable, and can be used several times (hopefully).
This becomes very useful if it comes in smaller doses than the current vials.
If they stick with the current dose amount, it’s value is much more limited. It then becomes an option only in the “almost unconscious” scenarios. That would be unfortunate.
A smaller dose gives you the option to take it yourself when dropping, or when you have made a bolus mistake.